• Organizations: ANI Pharmaceuticals
FDA approves expanded label of ILUVIEN for chronic posterior uveitis
Products

FDA approves expanded label of ILUVIEN for chronic posterior uveitis

Updated label for sustained-release fluocinolone acetonide intravitreal implant now includes noninfectious uveitis affecting the posterior segment of the eye.
ANI Pharmaceuticals receives FDA approval for Purified Cortrophin Gel PFS
Products

ANI Pharmaceuticals receives FDA approval for Purified Cortrophin Gel PFS

Prefilled syringe of corticotropin injection reduces administration steps for patients with inflammatory eye diseases like allergic conjunctivitis, keratitis, and optic neuritis.
ANI Pharmaceuticals officially acquires Alimera Sciences
Business

ANI Pharmaceuticals officially acquires Alimera Sciences

Purchase includes YUTIQ and ILUVIEN, expanding the company’s ophthalmic presence in the rare disease space.
ANI Pharmaceuticals to purchase Alimera Sciences
Business

ANI Pharmaceuticals to purchase Alimera Sciences

Acquisition expands ANI’s ophthalmic foothold with the addition of two FDA-approved therapeutics: ILUVIEN and YUTIQ.